Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Novo Nordisk

GE, Amazon Lead 5 Stocks Near Buy Points With This Bullish Trait

Relative strength is key when choosing top stocks. GE stock and Amazon stock pass the RS Line Blue Dot screen.

Investors Business Daily

Dow Jones Futures Rise, 3 Big Movers; Elon Musk's 'Actual Truth' Hits Tesla

Dow Jones Futures Rise, 3 Big Movers; Elon Musk's 'Actual Truth' Hits Tesla

The S&P 500 edged higher Thursday despite earnings losers. Leading stocks were resilient. Tesla fell after Elon Musk's 'actual truth' post.

Investors Business Daily

Novo Nordisk Eyes Another Breakout As Weight-Loss Battle Continues

Novo Nordisk Eyes Another Breakout As Weight-Loss Battle Continues

Novo Nordisk stock is Thursday's IBD Stock Of The Day after a study showed weight-loss drug, Wegovy, cut down on heart attacks and strokes.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Germany considers banning Ozempic exports, including to U.S.

Germany exports Ozempic to the EU and the U.S., Karl Broich, president of the German Federal Institute for Drugs and Medical Devices, told Der Spiegel.

Novo Nordisk Stock Skids — But These Weight-Loss Results Are 'Hard To Ignore'

Novo Nordisk stock slumped Monday despite unveiling promising test results for weight-loss drugs and diabetes development.

Investors Business Daily

Scientists have discovered a new benefit to Novo Nordisk’s weight-loss drug Wegovy: It can cut heart-related deaths by 20%, drugmaker reports

Wegovy was found to cut the risk of serious heart events by 20%—Novo Nordisk has now asked the U.S. FDA to reflect the heart benefits in the drug's label.

Obesity drug Wegovy cut risk of serious heart problems by 20%, study finds

A new large study finds that the popular weight-loss drug Wegovy reduced the risk of serious heart problems by 20% in certain patients

The Independent UK

inkl

Read news from The Economist, FT, and more,
with one subscription

Novo Nordisk faces first real test as Eli Lilly wins approval for a weight loss-aiding drug

Novo Nordisk faces first real test as Eli Lilly wins approval for a weight loss-aiding drug

U.S. regulators signed off on Eli Lilly’s diabetes drug Zepbound, which can also be used to aid weight loss like Wegovy and Ozempic.

AstraZeneca makes big push into weight-loss market with obesity pill deal

AstraZeneca makes big push into weight-loss market with obesity pill deal

UK drugmaker signs agreement with China’s Eccogene to work on an obesity and type 2 diabetes pill

The Guardian - UK

How a 'Rule of Two' could remove our barrier to better drug access

How a 'Rule of Two' could remove our barrier to better drug access

We need to address the unnecessary and wasteful Medsafe approval for tried and tested drugs by much bigger regulatory authorities abroad, argues Dr Eric Crampton

Novo Nordisk threatens to expand in US in row over EU rules

Novo Nordisk threatens to expand in US in row over EU rules

Novo Nordisk's CEO doesn't like proposed new EU rules that would cut the period for which drugmakers enjoy exclusivity for their products from 10 years to eight years.

Ozempic's rebranded weight-loss drug should be available next year

Ozempic's rebranded weight-loss drug should be available next year

'This is real and these medications are here to stay.'

Newcastle Herald

Novo Crushes Forecasts As Sales Of Weight-Loss Drug Rocket Eightfold

Novo Crushes Forecasts As Sales Of Weight-Loss Drug Rocket Eightfold

Novo Nordisk stock gapped up Thursday after reporting sweeping growth for weight-loss drug Wegovy, though Ozempic sales missed.

Investors Business Daily

Novo Nordisk gives foodmakers $900 million reason to worry

Novo Nordisk gives foodmakers $900 million reason to worry

Sales would have been higher if not for a shortfall following surging demand.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

Sales soar at Danish firm behind weight-loss drug semaglutide

Novo Nordisk says it struggling to keep up with demand after becoming Europe’s most valuable company

Investors Business Daily

Dow Jones Futures Rise: Market Rally Gains Steam On Fed Chief Powell's 'Decay'; Palantir Jumps

Techs led futures higher, with Palantir and Roku among the big earnings winners. Fed chief Jerome Powell signaled no more rate hikes, fueling Wednesday's strong market rally.

3 'Strong Buy' Dividend Stocks That Are Beating the Market

Here are three top-rated dividend stocks that have outperformed the S&P 500 in the past month, despite a tough environment for equities.

Investors Business Daily

Weight-Loss Drugs Spooked Medical Device Stocks. Did Investors Overreact?

The good times keep rolling for Novo Nordisk and its weight-loss drugs. But it's bad news for some medical device stocks.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Warning as patients hospitalised after taking fake Ozempic weight-loss drug

Hundreds of fake Ozempic jabs from the black market have been seied by the regulator

3 Top-Rated Growth Stocks To Buy on Every Dip

Growth stocks are down, but don't count them out. Here are three top-rated names worth scooping up when the market pulls back.

The Independent UK

Fears over black market weight loss drugs as people left seriously ill from counterfeit Ozempic

Austria’s criminal investigation service warned on Monday that fake injection pens may still be in circulation

Investors Business Daily

Stock Market Rallies, Hits Resistance; Novo Nordisk, JPMorgan, Exxon In Focus: Weekly Review

The major indexes rallied for the week, but hit resistance at key levels amid weak stock market breadth. Novo Nordisk, JPMorgan, Exxon were in focus.

Aust shares close a smidge higher to extend win streak

The local share market has technically extended its winning streak to six days, with seven of the ASX's 11 sectors finishing in the green.

Investors Business Daily

Stock Market Near The Day's Lows; AI-Focused Consulting Stock In Buy Zone

The stock market weakened in midday action as investors rethought higher-than-expected consumer price data, leaving major indexes mixed.

Investors Business Daily

Why Novo's Good News For Ozempic Slammed Dialysis Stocks DaVita And Fresenius

Novo Nordisk stock popped Wednesday after the company hinted Ozempic showed early promise in kidney disease treatment.

1 … 18 19 20 21

People

Lars Fruergaard Jørgensen

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

the Federal Reserve

Bank of America

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

300,122 stories

120,524 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play